A Phase 2 Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of MK-2214 in Participants With Early Alzheimer's Disease
Status: Recruiting
Location: See all (63) locations...
Intervention Type: Drug, Biological
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
Researchers want to know if the study treatment called MK-2214 works to slow certain changes in the brains of people with Alzheimer's disease (AD). AD is a type of dementia that can cause loss of memory, communication (such as speech), and decision-making skills. It can limit a person's ability to do daily tasks. MK-2214 is a study treatment designed to slow down AD. The goals of the study are to learn: * If MK-2214 slows the spread of tau in the brain compared to placebo. Tau is a protein that accumulates in AD \& damages brain cells. A placebo looks like the study treatment but has no study treatment in it. Using a placebo helps researchers better understand the effects of a study treatment. * About the safety of MK-2214 and if people tolerate it
Eligibility
Participation Requirements
Sex: All
Minimum Age: 50
Maximum Age: 85
Healthy Volunteers: f
View:
⁃ The main inclusion criteria include but are not limited to the following:
• Has mild cognitive impairment (MCI) or mild dementia due to Alzheimer's Disease (AD)
• Has a designated study partner who can fulfill the requirements of this study
• If on an approved AD therapy for symptomatic AD, the dosing regimen must have been stable for 3 months prior to screening
Locations
United States
California
Inglewood Clinical ( Site 1062)
RECRUITING
Inglewood
Irvine Clinical Research ( Site 1041)
RECRUITING
Irvine
Healthy Brain Clinic ( Site 1005)
RECRUITING
Long Beach
Anderson Clinical Research ( Site 1024)
RECRUITING
Redlands
UCSF Memory and Aging Center ( Site 1031)
RECRUITING
San Francisco
Syrentis Clinical Research ( Site 1001)
RECRUITING
Santa Ana
Connecticut
Yale University, Alzheimer's Disease Research Unit ( Site 1059)
RECRUITING
New Haven
Florida
JEM Research Institute ( Site 1046)
RECRUITING
Atlantis
Neuropsychiatric Research Center of Southwest Florida ( Site 1003)
RECRUITING
Fort Myers
Indago Research & Health Center, Inc ( Site 1044)
RECRUITING
Hialeah
K2 Medical Research ( Site 1047)
RECRUITING
Maitland
ClinCloud LLC ( Site 1039)
RECRUITING
Melbourne
Aqualane Clinical Research ( Site 1035)
RECRUITING
Naples
Suncoast Clinical Research ( Site 1007)
RECRUITING
New Port Richey
Renstar Medical Research ( Site 1012)
RECRUITING
Ocala
Charter Research - Orlando ( Site 1051)
RECRUITING
Orlando
Axiom Brain Health ( Site 1029)
RECRUITING
Tampa
K2 Medical Research Tampa LLC ( Site 1020)
RECRUITING
Tampa
Charter Research - Lady Lake ( Site 1019)
RECRUITING
The Villages
Conquest Research LLC ( Site 1053)
RECRUITING
Winter Park
Georgia
CenExel iResearch, LLC ( Site 1015)
RECRUITING
Decatur
Illinois
Alexian Brothers Medical Center-Neurosciences ( Site 1017)
RECRUITING
Elk Grove Village
Massachusetts
Boston Center for Memory ( Site 1008)
RECRUITING
Newton
Missouri
Clinical Research Professionals ( Site 1004)
RECRUITING
Chesterfield
New Jersey
The Cognitive and Research Center of New Jersey - Ridgewood ( Site 1064)
RECRUITING
Ridgewood
The Cognitive and Research Center of NJ ( Site 1057)
RECRUITING
Springfield
CenExel- AMRI ( Site 1018)
RECRUITING
Toms River
New York
Alzheimer Disease Research Center (ADRC) ( Site 1000)
RECRUITING
Albany
Mid Hudson Medical Research ( Site 1050)
RECRUITING
New Windsor
Basil Clinical ( Site 1065)
RECRUITING
Queens
Ohio
Insight Clinical Trials ( Site 1011)
RECRUITING
Independence
Neuro-Behavioral Clinical Research ( Site 1028)
RECRUITING
North Canton
Pennsylvania
Flourish Research ( Site 1048)
RECRUITING
Plymouth Meeting
Texas
Gadolin Research ( Site 1032)
RECRUITING
Beaumont
Horizon Clinical Research Center - Houston ( Site 1026)
RECRUITING
Cypress
Other Locations
Argentina
Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia (FLENI) ( Site 0400)
RECRUITING
Caba
Australia
KARA Institute for Neurological Diseases ( Site 0302)
RECRUITING
Macquarie Park
Belgium
AZ Groeninge Campus Kennedylaan ( Site 3002)
RECRUITING
Kortrijk
Japan
Inage Neurology and Memory Clinic ( Site 9001)
RECRUITING
Chiba
Kyushu University Hospital ( Site 9010)
RECRUITING
Fukuoka
National Hospital Organization Hizen Psychiatric Medical Center ( Site 9004)
RECRUITING
Kanzaki-gun
Association of Healthcare Corporation Koukankai Koukan Clinic ( Site 9016)
RECRUITING
Kawasaki
Katayama Medical Clinic ( Site 9005)
RECRUITING
Kurashiki
Chibaken Saiseikai Narashino Hospital ( Site 9000)
RECRUITING
Narashino
National Center for Geriatrics and Gerontology ( Site 9002)
RECRUITING
Ōbu
Okayama City General Medical Center Okayama City Hospital ( Site 9008)
RECRUITING
Okayama
Tokyo Medical University Hospital ( Site 9003)
RECRUITING
Shinjuku
Mie University Hospital ( Site 9011)
RECRUITING
Tsu
Netherlands
Brain Research Center Den Bosch B.V. ( Site 5001)
RECRUITING
's-hertogenbosch
Brain Research Center. ( Site 5000)
RECRUITING
Amsterdam
Brain Research Center Zwolle ( Site 5002)
RECRUITING
Zwolle
Republic of Korea
Ewha Womans University Seoul Hospital ( Site 0201)
RECRUITING
Seoul
Hanyang University Hospital ( Site 0200)
RECRUITING
Seoul
Spain
Fundació ACE ( Site 6003)
RECRUITING
Barcelona
Hospital Clinic i Provincial ( Site 6002)
RECRUITING
Barcelona
Hospital del Mar ( Site 6001)
RECRUITING
Barcelona
Hospital Universitari Mutua Terrassa ( Site 6004)
RECRUITING
Terrassa
United Kingdom
Scottish Brain Sciences Aberdeen ( Site 8001)
RECRUITING
Aberdeen
Remind UK ( Site 8003)
RECRUITING
Bath
Re:Cognition Health - Birmingham ( Site 8002)
RECRUITING
Birmingham
Scottish Brain Sciences ( Site 8000)
RECRUITING
Edinburgh
Warneford Hospital ( Site 8007)
RECRUITING
Oxford
Moorgreen Hospital ( Site 8004)
RECRUITING
Southampton
Contact Information
Primary
Toll Free Number
Trialsites@msd.com
1-888-577-8839
Time Frame
Start Date: 2025-07-16
Estimated Completion Date: 2029-04-30
Participants
Target number of participants: 340
Treatments
Experimental: MK-2214
Participants will receive MK-2214 via intravenous (IV) infusion every 4 weeks (q4w) during the study.
Placebo_comparator: Placebo
Participants will receive a placebo via IV infusion q4w during the study.
Related Therapeutic Areas
Sponsors
Leads: Merck Sharp & Dohme LLC